Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Lancet (London, England)|December 18, 2020
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trialRobert Croop, Richard B Lipton, David Kudrow, et al.Journal of Pain Research|July 16, 2021
Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster HeadacheJ Scott Andrews, David Kudrow, Mallikarjuna Rettiganti, et al.Headache|March 21, 2023
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial dataDavid Kudrow, Rima Dafer, David W Dodick, et al.Cephalalgia : an International Journal of Headache|February 24, 2018
ARISE: A Phase 3 randomized trial of erenumab for episodic migraineDavid W Dodick, Messoud Ashina, Jan Lewis Brandes, et al.The Journal of Headache and Pain|November 25, 2021
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studiesStephanie J Nahas, Steffen Naegel, Joshua M Cohen, et al.Cephalalgia : an International Journal of Headache|August 19, 2021
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studiesRichard B Lipton, David W Dodick, David Kudrow, et al.Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 18, 2025
Safety and efficacy of pegtibatinase enzyme replacement therapy in adults with classical homocystinuria in the COMPOSE® phase 1/2 randomized trialCan Ficicioglu, Janet A Thomas, Jaya Ganesh, et al.Cephalalgia : an International Journal of Headache|December 3, 2020
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extensionRichard B Lipton, Stewart J Tepper, Stephen D Silberstein, et al.JAMA|April 5, 2007
Sumatriptan-naproxen for acute treatment of migraine: a randomized trialJan Lewis Brandes, David Kudrow, Stuart R Stark, et al.Pageof 4